MTOR and Alzheimer disease: gingivalis macrolide antibiotic and mTOR modulator, was found to have senotherapeutic properties, indicating potential benefits in AD (Maezono et al., 2011; Ratzinger et al., 2014; Ozsvari et al., 2018; Weng et al., 2019).